Recently, TrialSite News reported on a study sponsored in Bangladesh by Upazila Health & Family Planning Officer’s (UHFPO) Office, Chakoria, Cox’ Bazar and Abu Taiub Mohammad Mohiuddin Chowdhury, First Affiliated Hospital Xi’an Jiaotong University. The observational study was conducted from May 2 to June 5, 2020. The principal investigators observed 181 patients who tested positive for COVID-19. The Research team recently shared the results via preprint server and ResearchGate. The study team concluded that concerning the treatment outcome, adverse effect, and safety, the Ivermectin and Doxycycline combination was superior to the use of Hydroxychloroquine and Azithromycin therapy in the case of mild to moderate degree of COVID-19 patients. Although both treatment regimens were observed to be effective for this study, the Ivermectin treatment was superior.
Sponsored by Upazila Health & Family Planning Officer’s (UHFPO) Office, Chakoria, Cox’s Bazar in collaboration with Abu Taiub Mohammad Mohiuddin Chowdhury, First Affiliated Hospital Xi’an Jiaotong University, China, this study was conducted for just over a month from May to June 2020. ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).